JP2016529235A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529235A5
JP2016529235A5 JP2016526992A JP2016526992A JP2016529235A5 JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5 JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5
Authority
JP
Japan
Prior art keywords
optionally
amino
group
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526992A
Other languages
English (en)
Japanese (ja)
Other versions
JP6653253B2 (ja
JP2016529235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/046203 external-priority patent/WO2015009545A1/en
Publication of JP2016529235A publication Critical patent/JP2016529235A/ja
Publication of JP2016529235A5 publication Critical patent/JP2016529235A5/ja
Application granted granted Critical
Publication of JP6653253B2 publication Critical patent/JP6653253B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526992A 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのn−尿素置換アミノ酸の誘導体 Expired - Fee Related JP6653253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846787P 2013-07-16 2013-07-16
US61/846,787 2013-07-16
PCT/US2014/046203 WO2015009545A1 (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Publications (3)

Publication Number Publication Date
JP2016529235A JP2016529235A (ja) 2016-09-23
JP2016529235A5 true JP2016529235A5 (OSRAM) 2017-08-17
JP6653253B2 JP6653253B2 (ja) 2020-02-26

Family

ID=51230227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526992A Expired - Fee Related JP6653253B2 (ja) 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのn−尿素置換アミノ酸の誘導体

Country Status (11)

Country Link
US (1) US9428549B2 (OSRAM)
EP (1) EP3022174B1 (OSRAM)
JP (1) JP6653253B2 (OSRAM)
KR (1) KR102313757B1 (OSRAM)
CN (1) CN105377814B (OSRAM)
AU (1) AU2014290618B2 (OSRAM)
CA (1) CA2917811C (OSRAM)
DK (1) DK3022174T3 (OSRAM)
ES (1) ES2708571T3 (OSRAM)
RU (1) RU2696581C2 (OSRAM)
WO (1) WO2015009545A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518742B (zh) 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
BR112015021392B1 (pt) 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
WO2015077451A1 (en) 2013-11-21 2015-05-28 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
BR112016011755B1 (pt) 2013-11-28 2023-05-02 Kyorin Pharmaceutical Co., Ltd Derivado de ureia ou sal farmacologicamente aceitável do mesmo, seu uso e composição farmacêutica que os compreende
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
AU2015264021B2 (en) 2014-05-21 2020-02-27 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
BR112017024966A2 (pt) 2015-05-27 2018-08-07 Kyorin Seiyaku Kk derivado de ureia ou sal farmacologicamente aceitável do mesmo
WO2017023907A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) * 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
ATE212356T1 (de) * 1994-02-09 2002-02-15 Shionogi & Co Carbamoylmethylharnstoffderivate
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
US6548637B1 (en) * 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
WO2003082314A2 (en) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
EP1692502A2 (en) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
HRP20130972T1 (hr) * 2009-05-18 2013-11-22 Actelion Pharmaceuticals Ltd. Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
CN106518742B (zh) * 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8735622B2 (en) * 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
BR112015021392B1 (pt) * 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
BR112015021371B1 (pt) * 2013-03-06 2021-04-13 Allergan, Inc Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares

Similar Documents

Publication Publication Date Title
JP2016529235A5 (OSRAM)
JP2017537940A5 (OSRAM)
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2016530310A5 (OSRAM)
JP2019514874A5 (OSRAM)
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2016536364A5 (OSRAM)
JP2016536363A5 (OSRAM)
JP2014511892A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2017523225A5 (OSRAM)
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2014502979A5 (OSRAM)
JP2017517538A5 (OSRAM)
JP2015508092A5 (OSRAM)
JP2016531126A5 (OSRAM)
JP2015535847A5 (OSRAM)
JP2018048143A5 (OSRAM)
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2016528273A5 (OSRAM)
JP2020511547A5 (OSRAM)
JP2004525183A5 (OSRAM)
JP2018530582A5 (OSRAM)
JP2019512533A5 (OSRAM)